DeepTek launches global access pricing

DeepTek has announced Global Access Pricing, a new pricing model enabled through its access agreement with Unitaid and the Clinton Health Access Initiative (CHAI).

This initiative makes DeepTek’s WHO-recommended Chest X-ray AI solution more affordable for eligible public sector and not-for-profit healthcare providers across 138 low- and middle-income countries (LMICs), helping national TB programmes expand access to high-quality AI-assisted screening within existing budgets.

Global Access Pricing enables eligible health systems to access DeepTek’s WHO-recommended Chest X-ray AI solution at approximately one-third of its previous pricing. By significantly reducing the cost of deployment, the new access model enables programmes to screen up to three times more people within existing budgets helping expand screening coverage, reach underserved communities, strengthen case finding, and accelerate earlier diagnosis without compromising on diagnostic quality.

The annual subscription includes unlimited AI analyses per connected X-ray unit, installation, user training, product updates, maintenance, and technical support —all with no hidden add-on costs. The solution supports online, offline and hybrid deployment, enabling implementation across hospitals, diagnostic centres, mobile screening units and remote healthcare facilities, even in low-connectivity settings.

Beyond TB screening, DeepTek’s AI detects 20+ clinically relevant chest abnormalities, enabling healthcare providers to maximise the value of every chest X-ray while supporting broader lung health programmes and improving the efficiency of existing imaging infrastructure. Global Access Pricing also establishes transparent pricing for additional indications, such as cardiomegaly, silicosis, and lung cancer, enabling health systems to expand from TB screening to broader lung health screening through a single chest X-ray AI solution.

Ajit Patil, Co-founder and MD, DeepTek said, “At DeepTek, we believe healthcare programmes should never have to choose between quality and affordability. Global Access Pricing brings our WHO-recommended Chest X-ray AI within reach of more healthcare programmes through a transparent model designed for scale. By enabling programmes to screen more people with the same trusted technology, we hope to accelerate earlier TB detection and expand equitable access to quality diagnostics.” 

Dr Amit Kharat, Co-founder & CEO, DeepTek said, “AI has transformed what is possible in TB screening. The opportunity now is to make that capability accessible at scale. Through Global Access Pricing, we are enabling healthcare programmes to deploy WHO-recommended AI more widely, helping more people benefit from earlier detection and timely care.” — 

Dr Philippe Duneton, Executive Director, Unitaid said, “By working with DeepTek to reduce the cost of AI interpretation software, we are helping make proven digital health innovations more accessible to countries. At a time when funding constraints are threatening progress in tuberculosis detection, reducing the cost of diagnostic tools is critical to expanding access to timely diagnosis and care and ensuring more people can benefit.”

“AI-powered chest X-ray screening means health systems can efficiently identify those with potential TB disease, even when radiologists are not available,” said Marie Chantale Lepine, Vice President of Global Markets at CHAI. “Cutting the annual licensing cost means high burden countries can equip more mobile clinics and community health centers with the tools to expand TB screening services to identify TB early.”